@article{14d02f176f704078bdc98b89cfc576f8,
title = "MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer",
abstract = "MicroRNA deregulation is frequent in human colorectal cancers (CRCs), but little is known as to whether itrepresents a bystander event or actually drives tumor progression invivo. We show that miR-135b overexpression is triggered in mice and humans by APC loss, PTEN/PI3K pathway deregulation, and SRC overexpression and promotes tumor transformation and progression. We show that miR-135b upregulation is common in sporadic and inflammatory bowel disease-associated human CRCs and correlates with tumor stage and poor clinical outcome. Inhibition of miR-135b in CRC mouse models reduces tumor growth by controlling genes involved in proliferation, invasion, and apoptosis. We identify miR-135b as a key downsteam effector of oncogenic pathways and a potential target for CRC treatment.",
author = "Nicola Valeri and Chiara Braconi and Pierluigi Gasparini and Claudio Murgia and Andrea Lampis and Viola Paulus-Hock and Hart, \{Jonathan R.\} and Lynn Ueno and Grivennikov, \{Sergei I.\} and Francesca Lovat and Alessio Paone and Luciano Cascione and Sumani, \{Khlea M.\} and Angelo Veronese and Muller Fabbri and Stefania Carasi and Hansjuerg Alder and Giovanni Lanza and Roberta Gafa' and Moyer, \{Mary P.\} and Ridgway, \{Rachel A.\} and Julia Cordero and Nuovo, \{Gerard J.\} and Frankel, \{Wendy L.\} and Massimo Rugge and Matteo Fassan and Joanna Groden and Vogt, \{Peter K.\} and Michael Karin and Sansom, \{Owen J.\} and Croce, \{Carlo M.\}",
note = "Funding Information: The work was supported by the Kimmel Cancer Foundation Translational Scholar Award to N.V. and by NIH grants U01 CA152758 and RC2 CA148302 to C.M.C., 1R01 CA078230 to P.K.V., and NIH (AI043477; DK035108) and AACR (07-60-21-KARI) grants to M.K., who is an American Cancer Society Research Professor. S.I.G. was supported by Crohn{\textquoteright}s and Colitis Foundation of America (Career Development award no. 2693) and NIH/NIDDK (K99-DK088589). N.V. is the recipient of a Cancer Research UK Career Establishment award (A18052) and a Marie Curie Integration grant (TamiRCRT). C.B. is the recipient of a Scottish Senior Clinical Research Fellowship and recipient of a Chief Scientist Office grant. We acknowledge support from the National Institutes for Health Research Royal Marsden-Institute of Cancer Research Biomedical Research Centre. We thank Prof. Bert Vogelstein, Johns Hopkins University for the PIK3CA isogenic cell lines. ",
year = "2014",
month = apr,
day = "14",
doi = "10.1016/j.ccr.2014.03.006",
language = "English (US)",
volume = "25",
pages = "469--483",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "4",
}